202 related articles for article (PubMed ID: 16250846)
1. Pharmacological intervention of cyclooxygenase-2 and 5-lipoxygenase pathways. Impact on inflammation and cancer.
Clària J; Romano M
Curr Pharm Des; 2005; 11(26):3431-47. PubMed ID: 16250846
[TBL] [Abstract][Full Text] [Related]
2. New approaches to the modulation of the cyclooxygenase-2 and 5-lipoxygenase pathways.
González-Périz A; Clària J
Curr Top Med Chem; 2007; 7(3):297-309. PubMed ID: 17305572
[TBL] [Abstract][Full Text] [Related]
3. Synthetically-tailored and nature-derived dual COX-2/5-LOX inhibitors: Structural aspects and SAR.
Meshram MA; Bhise UO; Makhal PN; Kaki VR
Eur J Med Chem; 2021 Dec; 225():113804. PubMed ID: 34479036
[TBL] [Abstract][Full Text] [Related]
4. Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers.
Khanapure SP; Garvey DS; Janero DR; Letts LG
Curr Top Med Chem; 2007; 7(3):311-40. PubMed ID: 17305573
[TBL] [Abstract][Full Text] [Related]
5. Dual acting anti-inflammatory drugs: a reappraisal.
Bertolini A; Ottani A; Sandrini M
Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy.
Romano M; Claria J
FASEB J; 2003 Nov; 17(14):1986-95. PubMed ID: 14597668
[TBL] [Abstract][Full Text] [Related]
7. Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept.
Celotti F; Laufer S
Pharmacol Res; 2001 May; 43(5):429-36. PubMed ID: 11394934
[TBL] [Abstract][Full Text] [Related]
8. Two-pronged approach to anti-inflammatory therapy through the modulation of the arachidonic acid cascade.
Sala A; Proschak E; Steinhilber D; Rovati GE
Biochem Pharmacol; 2018 Dec; 158():161-173. PubMed ID: 30315753
[TBL] [Abstract][Full Text] [Related]
9. DuCLOX-2/5 inhibition: a promising target for cancer chemoprevention.
Gautam S; Roy S; Ansari MN; Saeedan AS; Saraf SA; Kaithwas G
Breast Cancer; 2017 Mar; 24(2):180-190. PubMed ID: 27558792
[TBL] [Abstract][Full Text] [Related]
10. Regulation of tumorigenic Wnt signaling by cyclooxygenase-2, 5-lipoxygenase and their pharmacological inhibitors: A basis for novel drugs targeting cancer cells?
Roos J; Grösch S; Werz O; Schröder P; Ziegler S; Fulda S; Paulus P; Urbschat A; Kühn B; Maucher I; Fettel J; Vorup-Jensen T; Piesche M; Matrone C; Steinhilber D; Parnham MJ; Maier TJ
Pharmacol Ther; 2016 Jan; 157():43-64. PubMed ID: 26549540
[TBL] [Abstract][Full Text] [Related]
11. Potent inhibition of human 5-lipoxygenase and microsomal prostaglandin E₂ synthase-1 by the anti-carcinogenic and anti-inflammatory agent embelin.
Schaible AM; Traber H; Temml V; Noha SM; Filosa R; Peduto A; Weinigel C; Barz D; Schuster D; Werz O
Biochem Pharmacol; 2013 Aug; 86(4):476-86. PubMed ID: 23623753
[TBL] [Abstract][Full Text] [Related]
12. Dual COX-2/15-LOX inhibitors: A new avenue in the prevention of cancer.
Aliabadi A; Khanniri E; Mahboubi-Rabbani M; Bayanati M
Eur J Med Chem; 2023 Dec; 261():115866. PubMed ID: 37862815
[TBL] [Abstract][Full Text] [Related]
13. Celastrol modulates inflammation through inhibition of the catalytic activity of mediators of arachidonic acid pathway: Secretory phospholipase A
Joshi V; Venkatesha SH; Ramakrishnan C; Nanjaraj Urs AN; Hiremath V; Moudgil KD; Velmurugan D; Vishwanath BS
Pharmacol Res; 2016 Nov; 113(Pt A):265-275. PubMed ID: 27597642
[TBL] [Abstract][Full Text] [Related]
14. High-throughput screening assays for cyclooxygenase-2 and 5-lipoxygenase, the targets for inflammatory disorders.
Kumar KA; Reddy TC; Reddy GV; Reddy DB; Mahipal SV; Sinha S; Gaikwad AN; Reddanna P
Indian J Biochem Biophys; 2011 Aug; 48(4):256-61. PubMed ID: 22053694
[TBL] [Abstract][Full Text] [Related]
15. Lipoxygenase Inhibitors as Cancer Chemopreventives: Discovery, Recent Developments and Future Perspectives.
Mahboubi-Rabbani M; Zarghi A
Curr Med Chem; 2021; 28(6):1143-1175. PubMed ID: 31820690
[TBL] [Abstract][Full Text] [Related]
16. The shunting of arachidonic acid metabolism to 5-lipoxygenase and cytochrome p450 epoxygenase antagonizes the anti-cancer effect of cyclooxygenase-2 inhibition in head and neck cancer cells.
Park SW; Heo DS; Sung MW
Cell Oncol (Dordr); 2012 Feb; 35(1):1-8. PubMed ID: 21656078
[TBL] [Abstract][Full Text] [Related]
17. Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor.
Horrillo R; Planagumà A; González-Périz A; Ferré N; Titos E; Miquel R; López-Parra M; Masferrer JL; Arroyo V; Clària J
J Pharmacol Exp Ther; 2007 Dec; 323(3):778-86. PubMed ID: 17766677
[TBL] [Abstract][Full Text] [Related]
18. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy?
Fiorucci S; Meli R; Bucci M; Cirino G
Biochem Pharmacol; 2001 Dec; 62(11):1433-8. PubMed ID: 11728379
[TBL] [Abstract][Full Text] [Related]
19. Involvement of eicosanoids in the pathogenesis of pancreatic cancer: the roles of cyclooxygenase-2 and 5-lipoxygenase.
Knab LM; Grippo PJ; Bentrem DJ
World J Gastroenterol; 2014 Aug; 20(31):10729-39. PubMed ID: 25152576
[TBL] [Abstract][Full Text] [Related]
20. The different inhibitory effects of Huang-Lian-Jie-Du-Tang on cyclooxygenase 2 and 5-lipoxygenase.
Li L; Zeng H; Shan L; Yuan X; Li Y; Liu R; Zhang W
J Ethnopharmacol; 2012 Sep; 143(2):732-9. PubMed ID: 22884869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
